Pharmaceutical

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer.

Aug 30, 2023 - 20:00
Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer.
Read the original article

Tags:

Previous Article

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Next Article

Boston Scientific’s Farapulse System Irregular Heartbeat Treatment 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alfasigma to buy Intercept Pharmaceuticals for $794m

Alfasigma to buy Intercept Pharmaceuticals for $794m

Sep 27, 2023

FDA approves Astellas’ VYLOY for gastric cancer treatment

FDA approves Astellas’ VYLOY for gastric cancer treatment

Oct 22, 2024

Sosei to regain rights to IBD drug after GSK discontinues programme

Sosei to regain rights to IBD drug after GSK discontinu...

Nov 24, 2023